Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27621012 | 0.85 | MAPK1 (0.47) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL16769968 | 0.82 | MAPK1 (0.52) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL4129784 | 0.82 | MAPK1 (0.52) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL12361793 | 0.81 | CYP2C9 (0.47) | MAPTCYP4F2CYP4A11TSHRCA12 | |
| SCHEMBL25213656 | 0.81 | MAPK1 (0.50) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL25659556 | 0.80 | CA12 (0.36) | MAPK1ALDH1A1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL28379955 | 0.79 | LOXL2 (0.50) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL19776257 | 0.79 | MAPK1 (0.49) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL1810517 | 0.78 | MAPK1 (0.47) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL18547783 | 0.78 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680602-A1 | HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS | Miralinc Pharma, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-4446323-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | Shanghai Visonpharma Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024192237-A1 | HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS | MIRALINC PHARMA, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| WO-2023104165-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | 上海维申医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
| CN-111848629-B | mTOR/HDAC dual inhibitor and application thereof | 安徽中医药大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-111848629-A | mTOR/HDAC dual inhibitor and application thereof | 安徽中医药大学 | 2020-10-30 | — | — | CN | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| CN-110627801-A | HDAC inhibitor and application thereof | 安徽中医药大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| EP-3328843-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017018803-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017018803-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-02-02 | — | — | WO | disclosed |
| EP-1555259-B1 | Malononitrile compounds as pesticides | SUMITOMO CHEMICAL CO (JP) | 2008-01-02 | — | — | EP | disclosed |
| EP-1555259-A1 | Malononitrile compounds as pesticides | Sumitomo Chemical Company, Limited (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | MAPK1 2286/4885KDM4E 689/4885L3MBTL1 4662/4885 |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | MAPK1 4224/4885KDM4E 4045/4885L3MBTL1 2346/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | MAPK1 2380/4885KDM4E 562/4885L3MBTL1 1844/4885 |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | TLR7, TLR8, TLR1 | MAPK1 350/4885KDM4E 2160/4885L3MBTL1 3110/4885 |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC5, HDAC2 | MAPK1 1931/4885KDM4E 1285/4885L3MBTL1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.